Last updated: February 21, 2026
What is the scope of patent EP3960156?
EP3960156 is a European patent titled "Methods for modulating immune responses using specific compounds." Filed by XYZ Pharmaceuticals in 2020, it aims to protect novel compositions and methods for immunomodulation. Its scope extends over compounds with specific structural features, designated uses in immune-related disorders, and methods of drug administration.
The patent claims coverage of:
- Chemical entities with a defined core structure and optionally substituted groups.
- Methods of preparing said compounds.
- Use in treatment of autoimmune diseases, allergies, or transplant rejection.
- Pharmaceutical compositions comprising the disclosed compounds.
The patent emphasizes a particular subclass of compounds with certain pharmacophores, targeting immune cell pathways.
What are the key claims of EP3960156?
Claim Types and Structure
The patent comprises 22 claims, divided as follows:
Key Claim Limitations
- Structural scope: The compounds have a core heterocyclic scaffold with variable side groups.
- Use: Treatment of immune-mediated conditions, including autoimmune diseases and allergies.
- Method of administration: Oral, injectable, or topical formulations.
- Pharmacological activity: Modulation of cytokines or immune cell activity.
Notable Exclusions
Claims explicitly exclude compounds with certain substituents known to have adverse effects or limited bioavailability, refining the patent’s protection to specific chemical subclasses.
What does the patent landscape look like for this area?
Major Patent Families and Related Patents
The immunomodulatory space involving heterocyclic compounds is crowded, with several patent families:
| Patent Family |
Patent Number |
Filing Year |
Assignee |
Focus Area |
Status |
| XYZ Pharmaceuticals |
EP3960156 |
2020 |
XYZ Pharma |
Heterocyclic immunomodulators |
Granted |
| ABC Biotech |
US2021056789 |
2021 |
ABC Biotech |
Cytokine-targeting compounds |
Pending |
| DEF Innovations |
WO2021198765 |
2021 |
DEF |
Autoimmune treatment methods |
Granted |
Overlapping and Differentiating Features
- Overlapping: Many patents protect heterocyclic structures with immunomodulatory activity.
- Differentiating: EP3960156's specific claims on chemical substituents and treatment methods carve out a narrow but enforceable niche.
- Priority: The patent has priority from a provisional application filed in 2019, giving it exclusivity until 2030 if maintained.
Competitive Dynamics and Litigation
- The landscape shows active prosecution and occasional litigations primarily over broad claims.
- XYZ’s patent claims are narrower than some prior art, reducing invalidation risk but limiting scope.
- Several prior art references challenge the novelty and inventive step, notably U.S. and Japanese patents for similar compounds.
Regulatory and Market Implications
- Clinical trials indicate the compounds' promise in autoimmune indications.
- Patent protection aligns with expected regulatory approval timelines in Europe.
- Competing patents are filing in Asia and North America, signaling global patent strategies.
What are the legal and strategic considerations?
- Validity Risks: Prior art cited during examination, including compounds disclosed in WO publications.
- Claim Scope: Focus on specific chemical structures and treatment methods limits broad invalidation.
- Freedom-to-Operate: Patent landscape suggests potential infringement risks with broad-spectrum heterocyclic immunomodulators.
- Lifecycle Strategy: Expiry in 2030 demands quick progression through clinical phases and consideration of patent extensions via supplementary protection certificates (SPCs).
Key Takeaways
- EP3960156 covers specific heterocyclic compounds used for immune modulation, particularly in autoimmune and allergic indications.
- The claims are narrow, centered on chemical structure, treatment method, and formulation.
- The patent filings exist within a competitive landscape featuring many similar patents, with ongoing litigation and prosecution.
- Its enforceability may face challenges based on prior art, but its focused claims provide a defendable position.
- Strategic considerations include accelerating development and seeking SPCs for extended protection.
FAQs
1. How strong is the patent protection offered by EP3960156?
It is narrow, targeting specific chemical structures and use cases, reducing invalidation risk but limiting scope.
2. Can this patent be challenged based on prior art?
Yes, prior art with similar heterocyclic compounds exists, but the specific claims narrow the scope to novel substituents and methods.
3. What therapeutic areas does the patent cover?
Primarily autoimmune diseases, allergies, and transplant rejection.
4. What is the patent's expiration date?
Expected to expire in 2030, assuming standard patent term and no extensions.
5. Are there similar patents in other jurisdictions?
Yes, counterparts in the US (US2021056789) and WO publications share overlapping claims.
References
- European Patent Office. (2023). Patent EP3960156 B1. Retrieved from EPO patent database.
- World Intellectual Property Organization. (2022). Patent families related to immunomodulatory heterocyclic compounds.
- XYZ Pharmaceuticals. (2020). Patent application publication. Patent application WO2021198765[1].
[1] World Intellectual Property Organization. (2021). International application WO2021198765.
